Skip to Content
Merck
  • RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.

RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.

Cancer cell (2008-09-06)
Kosei Ito, Anthony Chee-Beng Lim, Manuel Salto-Tellez, Lena Motoda, Motomi Osato, Linda Shyue Huey Chuang, Cecilia Wei Lin Lee, Dominic Chih-Cheng Voon, Jason Kin Wai Koo, Huajing Wang, Hiroshi Fukamachi, Yoshiaki Ito
ABSTRACT

In intestinal epithelial cells, inactivation of APC, a key regulator of the Wnt pathway, activates beta-catenin to initiate tumorigenesis. However, other alterations may be involved in intestinal tumorigenesis. Here we found that RUNX3, a gastric tumor suppressor, forms a ternary complex with beta-catenin/TCF4 and attenuates Wnt signaling activity. A significant fraction of human sporadic colorectal adenomas and Runx3(+/-) mouse intestinal adenomas showed inactivation of RUNX3 without apparent beta-catenin accumulation, indicating that RUNX3 inactivation independently induces intestinal adenomas. In human colon cancers, RUNX3 is frequently inactivated with concomitant beta-catenin accumulation, suggesting that adenomas induced by inactivation of RUNX3 may progress to malignancy. Taken together, these data demonstrate that RUNX3 functions as a tumor suppressor by attenuating Wnt signaling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid